PMC:7283670 / 55409-56573
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T201","span":{"begin":543,"end":548},"obj":"Body_part"},{"id":"T202","span":{"begin":886,"end":890},"obj":"Body_part"}],"attributes":[{"id":"A201","pred":"fma_id","subj":"T201","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A202","pred":"fma_id","subj":"T202","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experim"}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T133","span":{"begin":543,"end":548},"obj":"Body_part"}],"attributes":[{"id":"A133","pred":"uberon_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experim"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T339","span":{"begin":79,"end":87},"obj":"Disease"},{"id":"T340","span":{"begin":120,"end":128},"obj":"Disease"},{"id":"T341","span":{"begin":1038,"end":1046},"obj":"Disease"},{"id":"T342","span":{"begin":1120,"end":1128},"obj":"Disease"}],"attributes":[{"id":"A339","pred":"mondo_id","subj":"T339","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A340","pred":"mondo_id","subj":"T340","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A341","pred":"mondo_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A342","pred":"mondo_id","subj":"T342","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experim"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T536","span":{"begin":140,"end":142},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T537","span":{"begin":347,"end":348},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T538","span":{"begin":543,"end":548},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T539","span":{"begin":583,"end":588},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T540","span":{"begin":884,"end":890},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T541","span":{"begin":958,"end":963},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T542","span":{"begin":1008,"end":1009},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T543","span":{"begin":1066,"end":1071},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T544","span":{"begin":1139,"end":1141},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experim"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T65175","span":{"begin":33,"end":36},"obj":"Chemical"},{"id":"T42271","span":{"begin":95,"end":98},"obj":"Chemical"},{"id":"T66","span":{"begin":167,"end":172},"obj":"Chemical"},{"id":"T5227","span":{"begin":185,"end":188},"obj":"Chemical"},{"id":"T89603","span":{"begin":201,"end":209},"obj":"Chemical"},{"id":"T64472","span":{"begin":266,"end":281},"obj":"Chemical"},{"id":"T16097","span":{"begin":266,"end":275},"obj":"Chemical"},{"id":"T79085","span":{"begin":276,"end":281},"obj":"Chemical"},{"id":"T84596","span":{"begin":298,"end":301},"obj":"Chemical"},{"id":"T22462","span":{"begin":362,"end":367},"obj":"Chemical"},{"id":"T20379","span":{"begin":377,"end":385},"obj":"Chemical"},{"id":"T7585","span":{"begin":443,"end":458},"obj":"Chemical"},{"id":"T86024","span":{"begin":443,"end":452},"obj":"Chemical"},{"id":"T48066","span":{"begin":453,"end":458},"obj":"Chemical"},{"id":"T54548","span":{"begin":589,"end":596},"obj":"Chemical"},{"id":"T38531","span":{"begin":964,"end":975},"obj":"Chemical"},{"id":"T17203","span":{"begin":1072,"end":1083},"obj":"Chemical"}],"attributes":[{"id":"A69419","pred":"chebi_id","subj":"T65175","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A51503","pred":"chebi_id","subj":"T42271","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A42427","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A72432","pred":"chebi_id","subj":"T5227","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A83391","pred":"chebi_id","subj":"T89603","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A74762","pred":"chebi_id","subj":"T64472","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A30881","pred":"chebi_id","subj":"T16097","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A41384","pred":"chebi_id","subj":"T79085","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A27764","pred":"chebi_id","subj":"T84596","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A49896","pred":"chebi_id","subj":"T22462","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A81107","pred":"chebi_id","subj":"T20379","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A27789","pred":"chebi_id","subj":"T7585","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A96916","pred":"chebi_id","subj":"T86024","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A13695","pred":"chebi_id","subj":"T48066","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A80547","pred":"chebi_id","subj":"T54548","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A11733","pred":"chebi_id","subj":"T38531","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A42372","pred":"chebi_id","subj":"T17203","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"}],"text":"\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experim"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T607","span":{"begin":1,"end":353},"obj":"Sentence"},{"id":"T608","span":{"begin":354,"end":494},"obj":"Sentence"},{"id":"T609","span":{"begin":495,"end":562},"obj":"Sentence"},{"id":"T610","span":{"begin":563,"end":675},"obj":"Sentence"},{"id":"T611","span":{"begin":676,"end":799},"obj":"Sentence"},{"id":"T612","span":{"begin":800,"end":945},"obj":"Sentence"},{"id":"T613","span":{"begin":946,"end":1053},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experim"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"1807","span":{"begin":964,"end":995},"obj":"Gene"},{"id":"1808","span":{"begin":1072,"end":1103},"obj":"Gene"},{"id":"1879","span":{"begin":833,"end":836},"obj":"Gene"},{"id":"1880","span":{"begin":958,"end":963},"obj":"Species"},{"id":"1881","span":{"begin":1024,"end":1032},"obj":"Species"},{"id":"1882","span":{"begin":1066,"end":1071},"obj":"Species"},{"id":"2095","span":{"begin":79,"end":87},"obj":"Disease"},{"id":"2096","span":{"begin":120,"end":128},"obj":"Disease"},{"id":"2097","span":{"begin":1038,"end":1046},"obj":"Disease"},{"id":"2098","span":{"begin":1120,"end":1128},"obj":"Disease"}],"attributes":[{"id":"A1807","pred":"tao:has_database_id","subj":"1807","obj":"Gene:59272"},{"id":"A1808","pred":"tao:has_database_id","subj":"1808","obj":"Gene:59272"},{"id":"A1879","pred":"tao:has_database_id","subj":"1879","obj":"Gene:1401"},{"id":"A1880","pred":"tao:has_database_id","subj":"1880","obj":"Tax:9606"},{"id":"A1881","pred":"tao:has_database_id","subj":"1881","obj":"Tax:9606"},{"id":"A1882","pred":"tao:has_database_id","subj":"1882","obj":"Tax:9606"},{"id":"A2095","pred":"tao:has_database_id","subj":"2095","obj":"MESH:C000657245"},{"id":"A2096","pred":"tao:has_database_id","subj":"2096","obj":"MESH:C000657245"},{"id":"A2097","pred":"tao:has_database_id","subj":"2097","obj":"MESH:C000657245"},{"id":"A2098","pred":"tao:has_database_id","subj":"2098","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"\nClinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020\nRecombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experim"}